EFX的耐受性良好，最常见的不良事件是1级或2级胃肠道事件（腹泻、恶心和食欲增加）。 1例接受EFX治疗的患者因恶心而停药，1例在撤回同意后停药。

The case involved a clinical trial of Akero's only product, a drug candidate aimed at treating a liver disease. It's the ...

Investing.com - TD Cowen 对 Akero Therapeutics (NASDAQ: AKRO) 启动覆盖，给予买入评级，目标价为 76.00 美元。根据 InvestingPro 数据，这与分析师的强烈共识一致，目标价范围在每股 60 美元至 109 美元之间。该公司股票表现出令人印象深刻的增长势头，过去一年回报率达 92%。

Efx Fragments is available now at an introductory price of $99, though if you already own other Arturia products there's probably a steep discount waiting for you.